Equity offering with founder debt conversions · Biotech

Axelyf discloses equity financing with founder debt conversions

The reported securities total includes approximately $800,000 in conversions, leaving the exact new cash amount unspecified.

Axelyf reported $2,631,439 in securities sold to eight investors in a Form D filed on October 13, 2026. The notice explicitly includes approximately $800,000 of founder related debt and note conversions in that total.

The exact new cash amount is therefore unspecified. The offering began on October 7 and had $68,561 remaining against a $2.7 million target. The notice does not identify the subscribers or a named venture stage.

This is a new offering with a different first sale date from the company’s 2025 financing. Axelyf develops RNA medicines using its AXL lipid nanoparticle delivery platform, with programs for solid tumors and autoimmune disease.

Funding history

Equity offering with founder debt conversions · This roundUndisclosed

Sources

  1. Axelyf 2026 new equity offeringsec.gov · Oct 13, 2026
  2. Axelyf distinct 2025 financingsec.gov · Aug 7, 2025
  3. Axelyf RNA medicines and AXL platformaxelyf.com